| Title |
Prophylactic onabotulinumtoxinA in patients with chronic migraine and comorbid depression: An open-label, multicenter, pilot study of efficacy, safety and effect on headache-related disability, depression, and anxiety
|
|---|---|
| Published in |
International Journal of General Medicine, February 2015
|
| DOI | 10.2147/ijgm.s70456 |
| Pubmed ID | |
| Authors |
Guy P Boudreau, Brian M Grosberg, Peter J McAllister, Richard B Lipton, Dawn C Buse |
| Abstract |
Chronic migraine is associated with significant headache-related disability and psychiatric comorbidity. OnabotulinumtoxinA (BOTOX(®)) is effective and well tolerated in the prophylactic treatment of chronic migraine. This study aimed to provide preliminary data on the efficacy and safety of prophylactic onabotulinumtoxinA in patients with chronic migraine and comorbid depressive symptoms. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 65 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 2% |
| Unknown | 64 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 10 | 15% |
| Student > Master | 9 | 14% |
| Student > Doctoral Student | 9 | 14% |
| Student > Ph. D. Student | 8 | 12% |
| Other | 5 | 8% |
| Other | 16 | 25% |
| Unknown | 8 | 12% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 27 | 42% |
| Unspecified | 5 | 8% |
| Psychology | 3 | 5% |
| Nursing and Health Professions | 3 | 5% |
| Neuroscience | 3 | 5% |
| Other | 9 | 14% |
| Unknown | 15 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 January 2022.
All research outputs
#2,432,969
of 22,925,760 outputs
Outputs from International Journal of General Medicine
#117
of 1,457 outputs
Outputs of similar age
#36,987
of 353,180 outputs
Outputs of similar age from International Journal of General Medicine
#2
of 8 outputs
Altmetric has tracked 22,925,760 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,457 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.9. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 353,180 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one. This one has scored higher than 6 of them.